All In Biotech

Drug Trial Radar · NCT06162572

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

102

Actual

Start

Aug 7, 2024

Primary completion

Apr 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Servier Bio-Innovation LLCIndustry
Sponsor type
Industry
Collaborators
Institut de Recherches Internationales Servier; Regeneron Pharmaceuticals
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • S095018Drug

    Via IV infusion on Day 1 of each 21-day cycle

  • S095024Drug

    Via IV infusion on Day 1 of each 21-day cycle

  • S095029Drug

    Via IV infusion on Day 1 of each 21-day cycle

  • S095018 Recommended Dose Expansion (RDE)Drug

    Via IV infusion on Day 1 of each 21-day cycle

  • S095024 RDEDrug

    Via IV infusion on Day 1 of each 21-day cycle

  • S095029 RDEDrug

    Via IV infusion on Day 1 of each 21-day cycle

  • CemiplimabDrug

    350 mg via IV infusion on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatmentTime frame: Through the end of the Cycle 2 (each cycle is 21 days)
  2. Incidence and severity of adverse events (AEs)Time frame: From the signed informed consent form (ICF) to 30 days after the last dose
  3. Incidence and severity of serious adverse events (SAEs)Time frame: From the signed ICF to 120 days after the last dose
  4. Adverse Events (AEs) Leading to Dose Interruption, Modification, or DelaysTime frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
  5. Adverse Events (AEs) Leading to Permanent Treatment DiscontinuationTime frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
  6. Objective Response (OR)Time frame: Until study termination (approximately 2 years)

Locations

51 sites in 13 countries. Site status is shown where the registry gives one.

  • Henry Ford Health

    Detroit, Michigan

  • Gabrail Cancer Center

    Canton, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Border Medical Oncology Research Unit

    Albury, Australia

  • Flinders Medical Centre

    Bedford Park, Australia

  • Sunshine Hospital

    St Albans, Australia

  • Latrobe Regional Health

    Traralgon, Australia

  • Universitatsklinikum St. Poelten

    Sankt Pölten, Austria

  • Medical University of Vienna - Akh

    Vienna, Austria

  • Jessa Ziekenhuis

    Hasselt, Belgium

  • Hospital de Amor - Barretos

    Barretos, Brazil

  • Supera Oncologia

    Chapecó, Brazil

  • CIONC

    Curitiba, Brazil

  • Liga Contra O Cancer - Natal

    Natal, Brazil

  • Santa Casa de Porto Alegre

    Porto Alegre, Brazil

  • Hospital São Lucas Da Pucrs

    Porto Alegre, Brazil

  • Oncoclinicas Rj

    Rio de Janeiro, Brazil

  • Hospital A C Camargo

    São Paulo, Brazil

  • Hospital São Camilo

    São Paulo, Brazil

  • Oncoclinicas Sp

    São Paulo, Brazil

  • Hospital Albert Einstein

    São Paulo, Brazil

  • Centre Georges Francois Leclerc

    Dijon, France

  • Chu Grenoble Alpes

    Grenoble, France

  • Institut Paoli Calmette

    Marseille, France

  • Centre René Gauducheau/Inst de Cancér. de L'Ouest

    Saint-Herblain, France

  • Institut Gustave Roussy

    Villejuif, France

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Farkasgyepu Tudogyogyintezet

    Farkasgyepű, Hungary

  • Bugat Pal Hospital

    Gyöngyös, Hungary

  • Pecsi Tudomanyegyetem, Klinikai Kozpont

    Pécs, Hungary

  • Centro Di Riferimento Oncologico

    Aviano, Italy

  • Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori

    Meldola, Italy

  • Irccs Fondazione Istituto Nazionale Dei Tumori

    Milan, Italy

  • Istituto Europeo Di Oncologia

    Milan, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Ist. Nazionale Tumori Irccs Fondazione G Pascale

    Naples, Italy

  • Azienda Ospedaliera S. Maria Della Misericordia

    Perugia, Italy

  • Istituto Nazionale Tumori Regina Elena

    Roma, Italy

  • Istituto Clinico Humanitas I.R.C.C.S

    Rozzano, Italy

  • Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca

    Cluj-Napoca, Romania

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.